Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Estelamari Rodriguez"'
Publikováno v:
Health Psychology Research, Vol 12 (2024)
# Background The COVID-19 pandemic has not only caused unprecedented distress in the community but has also resulted in significant physical and psychological exhaustion among healthcare workers (HCWs). This exhaustion could potentially lead to seri
Externí odkaz:
https://doaj.org/article/f116460e0cb94df7a3c9112e76c09c73
Autor:
Samuel A. Kareff, Asaad Trabolsi, Harris B. Krause, Timothy Samec, Andrew Elliott, Estelamari Rodriguez, Coral Olazagasti, Dionysios C. Watson, Matias A. Bustos, Dave S. B. Hoon, Stephanie L. Graff, Emmanuel S. Antonarakis, Sanjay Goel, George Sledge, Gilberto Lopes
Publikováno v:
Cancers, Vol 16, Iss 8, p 1572 (2024)
Tipifarnib is the only targeted therapy breakthrough for HRAS-mutant (HRASmt) recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The molecular profiles of HRASmt cancers are difficult to explore given the low frequency of HRASmt.
Externí odkaz:
https://doaj.org/article/6987b80b5782400b895a7de9fe648443
Autor:
Esha Vallabhaneni, Samuel A. Kareff, Reagan M. Barnett, Leylah M. Drusbosky, Shivani Dalal, Luis E. Raez, Edgardo S. Santos, Federico Albrecht, Mike Cusnir, Estelamari Rodriguez
Publikováno v:
Cancers, Vol 16, Iss 6, p 1150 (2024)
Pathogenic germline variants (PGVs) may be under-detected as causative etiologies in patients with non-small cell lung cancer (NSCLC). The prevalence of PGVs has been reported between 1 and 15% of patients, depending on the patient population. The ra
Externí odkaz:
https://doaj.org/article/0d89f6e271ce48609d792257a10406ff
Autor:
Neelima Vidula, Andrew Lipman, Shumei Kato, Caroline Weipert, Katherine Hesler, Georges Azzi, Ahmed Elkhanany, Dejan Juric, Estelamari Rodriguez, Colleen Faulkner, Paul Makhlouf, Kristin Price, Joyce O’Shaughnessy, Aditya Bardia
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-7 (2022)
Abstract We evaluate microsatellite instability-high (MSI-H) status with cell-free DNA (cfDNA) in metastatic breast cancer (MBC) and the association with clinico-genomic characteristics. Patients with MSI-H in cfDNA (Guardant360®, 74 gene next-gener
Externí odkaz:
https://doaj.org/article/f65bfda34691462a94c380daea7a2c6a
Autor:
Samuel A. Kareff, Kunal Gawri, Khadeja Khan, Deukwoo Kwon, Estelamari Rodriguez, Gilberto de Lima Lopes, Richa Dawar
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Current first-line standard therapy for metastatic non-small cell lung cancer without driver mutations involves chemotherapy and immunotherapy combination. Prior to the advent of immune checkpoint inhibition, REVEL, a randomized phase III trial demon
Externí odkaz:
https://doaj.org/article/3276ac32e4964d1aab5b0cedacda126b
Publikováno v:
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-10 (2021)
Abstract METex14 skipping mutations occur in about 3–4% of lung adenocarcinoma patients and 1–2% of patients with other lung cancer histology. The MET receptor tyrosine kinase and its ligand hepatocyte growth factor (HGF) are established oncogeni
Externí odkaz:
https://doaj.org/article/9861e56c012246ee8994001ee6e06106
Publikováno v:
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-8 (2021)
Abstract The recent approvals by the Food and Drug Administration several tumor-agnostic drugs have resulted in a paradigm shift in cancer treatment from an organ/histology-specific strategy to biomarker-guided approaches. RET gene fusions are oncoge
Externí odkaz:
https://doaj.org/article/67f46a88af534e2eaafca57707e604e2
Autor:
Kathrin Dvir, Gliceida M. Galarza-Fortuna, Joel M. Haines, Paulina Gines, Ana L. Ruiz, Estelamari Rodriguez
Publikováno v:
Journal of Immunotherapy and Precision Oncology, Pp 1-5 (2021)
Introduction: The yield of adding plasma-based next-generation sequencing (NGS) to tissue NGS for the detection of actionable aberrations (AAs) has been reported; however, additional studies are needed to determine utility in the clinical setting. In
Externí odkaz:
https://doaj.org/article/13bfe99464f64ff8a1cdd0de14dd5058
Autor:
Rani Bansal, Julie McGrath, Phil Walker, Matias A. Bustos, Estelamari Rodriguez, Sarah L. Sammons, Melissa K. Accordino, Jane Meisel, Margaret Gatti-Mays, Emily Hsu, Kate I. Lathrop, Virginia Kaklamani, Matthew Oberley, W. Michael Korn, Stephanie L. Graff
Publikováno v:
Cancer Research. 83:HER2-12
Introduction: Breast cancer has pioneered precision medicine with prognostic and predictive subtypes, defined by immunohistochemistry (IHC). Novel therapeutic strategies have led to the emergence of HER2-Low (H2L) as a new entity, defined as tumors w
Publikováno v:
Clinical Lung Cancer. 23:457-466
Squamous cell carcinoma (SCC) of the lung has a markedly different molecular profile to adenocarcinoma of the lung and remains difficult to treat because of the lack of targeted therapies for this type of non-small cell lung cancer (NSCLC). With immu